United Therapeutics Corporation Release: OvaRex Phase III Trials Are Fully Enrolled

SILVER SPRING, Md. and WELLESLEY HILLS, Mass., June 20 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today that its wholly owned subsidiary Unither Pharmaceuticals, Inc. has reached full enrollment in its two pivotal trials of OvaRex(R) for the treatment of advanced ovarian cancer. IMPACT II, the second of two identical double-blind, placebo-controlled pivotal trials reached its enrollment goal of 177 patients and is now fully enrolled. IMPACT I reached its enrollment target in December of 2005. In addition, earlier this year full enrollment was achieved in a Phase II front-line trial of OvaRex in combination with chemotherapy, with a total of 40 patients enrolled.

OvaRex MAb-B43.13 (oregovomab) is an investigational immunotherapeutic monoclonal antibody being developed for the treatment of stage III/IV advanced ovarian cancer. OvaRex targets CA125, a protein expressed in most ovarian cancers, and is designed to help patients' immune systems recognize and more effectively fight their ovarian cancer.

The IMPACT I and II pivotal trials are designed to assess the time to disease relapse in patients diagnosed with late stage ovarian cancer, selected based on clinical and biomarker response to front-line treatment for their cancer, including debulking surgery and chemotherapy. All patients will continue on study until they experience progression of their disease, with the primary data analysis scheduled to occur after both trials have reported at least 118 relapse events each. Currently, relapse events in IMPACT I and IMPACT II are approximately 83% and 69% of the target, respectively. The two identical Phase III trials are being conducted at over 60 centers throughout the United States.

The Phase II trial of OvaRex in combination with front-line chemotherapy is designed to assess immune response in two dosing regimens. Primary analysis of this study is anticipated to be completed by the end of 2006.

"Achieving full enrollment in the Phase III IMPACT trials is an important milestone in the development of OvaRex and coincides with the completion of construction of our antibody laboratory," said Peter Gonze, Unither Pharmaceuticals' Chief Operating Officer.

Ovarian cancer is the fifth leading cause of cancer deaths among U.S. women. The American Cancer Society estimates that in the United States this year, there will be over 20,000 new cases diagnosed and over 15,000 women will die from ovarian cancer. Overall, the five-year survival rate for women with distant disease is estimated to be 29%. Although most patients initially respond to surgery and chemotherapy, the relapse rate is high and once relapse occurs, there is no known curative therapy.

June 22, 2006 Ovarian Cancer Investor and Analyst Day

As previously reported, United Therapeutics and Unither Pharmaceuticals will host an Investor and Analyst Day on Thursday, June 22, 2006 at their new laboratory located at 1040 Spring Street, Silver Spring, Maryland 20910 from 10:00 a.m. to 1:00 p.m. Eastern time. The event will include presentations from management focused on OvaRex and United Therapeutics' monoclonal antibody platform in general. The event will also include a tour of the new laboratory. Those interested in attending this event are asked to submit a reservation stating their name and affiliation by email to OVAREXRSVP@unither.com.

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life- threatening cardiovascular, cancer, and infectious diseases.

In addition to historical information, this press release contains forward-looking statements about expectations and intentions regarding the completion of the primary analysis of the Phase II trial of OvaRex in combination with front-line chemotherapy that are based on United Therapeutics' current beliefs and expectations as to future outcomes. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' periodic reports filed with the Securities and Exchange Commission which may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' periodic reports and documents filed with the Securities and Exchange Commission, including the company's most recent Form 10-K and Form 10-Q. United Therapeutics is providing this information as of June 20, 2006 and undertakes no obligation to publicly update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

United Therapeutics Corporation

CONTACT: Andrew Fisher of United Therapeutics Corporation,+1-301-608-9292, or Afisher@unither.com

Back to news